Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

BACKGROUND: There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this study was to evaluate the efficacy and tolerability of the modified FOLFIRINOX (mFFX) as a second-line therapy for MPC...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Sawada, Masashi, Kasuga, Akiyoshi, Mie, Takafumi, Furukawa, Takaaki, Taniguchi, Takanobu, Fukuda, Koshiro, Yamada, Yuto, Takeda, Tsuyoshi, Kanata, Ryo, Matsuyama, Masato, Sasaki, Takashi, Ozaka, Masato, Sasahira, Naoki
格式: Artigo
語言:Inglês
出版: BioMed Central 2020
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7238500/
https://ncbi.nlm.nih.gov/pubmed/32434547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06945-8
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍